Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
4'-(9-Acridinylamino)methanesulfon-m-anisidide (AMSA), a derivative of acridine, was evaluated in patients with advanced malignant neoplasms in a phase I clinical trial. The drug was administered in an iv infusion on a weekly x 4 schedule. Seventy-four courses of AMSA were administered to 34 patients over a dose range of 20-90 mg/m2. Dose-limiting toxicity, which was solely hematologic, was observed at 90 mg/m2. Objective antitumor effects were observed in two of 22 evaluable patients: a partial remission in a patient with abdominal desmoid fibrosarcomas and a minor regression in a patient with adenocarcinoma of the colon. A dose of 70-90 mg/m2 would be suitable for trials of AMSA on a weekly basis.
D000328:Adult; D000368:Aged; D000609:Aminoacridines / Q000008:administration & dosage* / Q000633:toxicity; D000677:Amsacrine; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced
D000609:Aminoacridines; D000970:Antineoplastic Agents; D000677:Amsacrine